RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM). Although RSV604 displays host-dependent potency against RSV cellular replication (EC50 = 2 μM/HeLa, 1.8 μM/HEp-2, >50 μM/BHK-21 based on cellular viral F protein level 72 hrs post RSV A2 infection) and release (by >1,000,000-fold/HeLa vs. no effect/BHK-21 72 hrs post infection; [RSV604] = EC90), complete loss of infectivity of released RSV from RSV604-treated cells is observed in both HeLa and BHK-21 cultures. RSV604 is also active against bovine RSV, but inactive toward mouse pneumonia virus, human metapneumovirus or parainfluenza virus types 1 &3 (PIV1 &PIV3).
Adv Healthc Mater. 2023 Aug 2;e2301325.
Combination Therapy with Resveratrol and Celastrol Using Folic Acid-Functionalized Exosomes Enhances the Therapeutic Efficacy of Sepsis
RSV604 (A-60444) purchased from AbMole
J Control Release. 2022 Dec 15;353:675-684.
Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia
RSV604 (A-60444) purchased from AbMole
| Molecular Weight | 388.39 |
| Formula | C22H17FN4O2 |
| CAS Number | 676128-63-5 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] SreeRupa Challa, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604
[4] James D Nokes, et al. New strategies for control of respiratory syncytial virus infection
[5] Joanna Chapman, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication
| Related RSV Products |
|---|
| 4,5-Di-O-caffeoylquinic acid methyl ester
4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratory syncytial virus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL. |
| RSV L-protein-IN-2
RSV L-protein-IN-2 is a noncompetitive RSV polymerase inhibitor (IC50: 4.5 μM). |
| RSV L-protein-IN-4
RSV L-protein-IN-4 is a noncompetitive RSV polymerase inhibitor (IC50: 0.88 μM). |
| RSV L-protein-IN-5
RSV L-protein-IN-5 is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.1 μM). |
| RSV L-protein-IN-1
RSV L-protein-IN-1 is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
